Effects of dezocine and sufentanyl for postoperative analgesia on activity of NK, CD4+ and CD8+ cells in patients with breast cancer

Wang, Fei; Zhao, Xue; Liu, Yi

doi:10.3892/ol.2019.9964

Cited by 10 publications

(11 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Emerging evidence has reported that dezocine could regulate immune function of cancer patients after surgery [19]. In this study, we investigated the anti-tumor activity of dezocine on ovarian cancer cells for the first time and demonstrated that dezocine could inhibited the viability of ES-2 and SKOV3 cells in a dose-independent manner.…”

Section: Discussionmentioning

confidence: 92%

“…Feng C et al previously reported that dezocine could regulate the secretion of IL-12 and IL-10 in dendritic cells, and enhance the activity of T cells during the maturation of dendritic cells, affecting immune function [18]. Wang F et al found that dezocine reduces the inhibitory effect of NK cells and CD4 + activity and the activity of CD8 + cells in breast cancer patients undergoing radical mastectomy, which is beneficial to the recovery of immune function [19]. These studies suggest that dezocine plays an important role in immune function.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Dezocine inhibits cell proliferation, migration and invasion by targeting CRABP2 in ovarian cancer

Zhang

Pan

et al. 2020

Preprint

View full text Add to dashboard Cite

Background Previous studies have shown that some anesthesia drugs can inhibit tumor growth and metastasis. As a clinical anesthetic drug, dezocine has been reported to play an important role in immune function. However, the effects of dezocine on ovarian cancer cell growth and metastasis are not fully understood. Results In this study, we found that dezocine dose-dependently inhibited the viability of ES-2 and SKOV3 cells. Dezocine suppressed the migration and invasion abilities of ovarian cancer cells, and promoted apoptosis. Moreover, the Akt/mTOR signaling pathway was also inhibited by dezocine. Furthermore, mechanism study showed that dezocine could significantly inhibited the expression of CRABP2, and CRABP2 overexpression reversed the inhibitory effects of dezocine on ovarian cancer cell proliferation and migration. Conclusion In conclusion, dezocine has significant anti-tumor effects on the growth and metastatic potential of ovarian cancer cells, and CRABP2 functions as a downstream effector of dezocine.

show abstract

Section: Discussionmentioning

confidence: 92%

Section: Introductionmentioning

confidence: 99%

Dezocine inhibits cell proliferation, migration and invasion by targeting CRABP2 in ovarian cancer

Zhang

Pan

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…Emerging evidence has reported that dezocine could regulate the immune function of cancer patients after surgery [19]. In this study, we investigated the anti-tumor activity of dezocine on ovarian cancer cells for the rst time and demonstrated that dezocine could inhibit the viability of ES-2 and SKOV3 cells in a dose-independent manner.…”

Section: Discussionmentioning

confidence: 93%

“…Feng C et al previously report that dezocine could regulate the secretion of IL-12 and IL-10 in dendritic cells and enhance the activity of T cells during the maturation of dendritic cells, affecting immune function [18]. Wang F et al show that dezocine reduces the inhibitory effect of NK cells and CD4 + activity and the activity of CD8 + cells in breast cancer patients undergoing radical mastectomy, which is bene cial to the recovery of immune function [19]. These studies suggest that dezocine plays an important role in immune function.…”

Section: Introductionmentioning

confidence: 98%

Dezocine inhibits cell proliferation, migration and invasion by targeting CRABP2 in ovarian cancer

Zhang¹,

R²,

Ma³

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Previous studies have shown that some anesthesia drugs can inhibit tumor growth and metastasis. As a clinical anesthetic drug, dezocine has been reported to play an important role in immune function. However, the effects of dezocine on ovarian cancer cell growth and metastasis are not fully understood. Results: In this study, we found that dezocine dose-dependently inhibited the viability of ovarian cancer ES-2 and SKOV3 cells. Dezocine suppressed the migration and invasion abilities of ovarian cancer cells and promoted apoptosis. Moreover, the Akt/mTOR signaling pathway was also inhibited by dezocine. Furthermore, the mechanism study showed that dezocine could significantly inhibit the expression of CRABP2, and CRABP2 overexpression reversed the inhibitory effects of dezocine on ovarian cancer cell proliferation and migration. Conclusions: In conclusion, dezocine has significant anti-tumor effects on the growth and metastatic potential of ovarian cancer cells, and CRABP2 functions as a downstream effector of dezocine.

show abstract

“…One study showed that dezocine was more beneficial to the recovery of the early postoperative immune function of patients with breast cancer undergoing postoperative analgesia after radical mastectomy. 10 A study by Song et al 17 revealed that dezocine can inhibit tumour metastasis by elevating CD8+ T cell proliferation and cytotoxicity. Zhu et al 32 revealed that dezocine and ropivacaine infiltration anaesthesia can significantly inhibit the secretion of pain factors in patients undergoing open hepatectomy, as well as reduce the stress response after surgery, reduce immune function fluctuations and help promote postoperative recovery.…”

Section: Discussionmentioning

confidence: 99%

Effect of Dezocine on the Ratio of Th1/Th2 Cytokines in Patients Receiving Postoperative Analgesia Following Laparoscopic Radical Gastrectomy: A Prospective Randomised Study

Feng

Chen³

et al. 2021

DDDT

View full text Add to dashboard Cite

Purpose To evaluate the effect of dezocine on the postoperative ratio of Th1/Th2 cytokines in patients undergoing laparoscopic radical gastrectomy. Patients and Methods Sixty patients undergoing laparoscopic radical gastrectomy were randomly divided into two groups (n=30): dezocine group (Group D) and sufentanil group (Group S). They received patient-controlled intravenous analgesia (PCIA) after the operation with either dezocine 0.8 mg/kg (Group D) or sufentanil 2 µg/kg (Group S). Both groups also received ondansetron 8 mg diluted to 100 mL with saline. The primary outcome was the Th1/Th2 cytokines ratio at predetermined intervals, 30 min before the induction of general anaesthesia and 0, 12, 24 and 48 h after surgery. The secondary endpoints were patients’ pain scores, measured on a visual analogue scale (VAS) at predetermined intervals (0, 12, 24 and 48 h after surgery), and side effects at follow-up 48 h after surgery. Results The Th1/Th2 cytokines ratio in Group D was significantly higher than Group S ( P <0.05) 12, 24 and 48 h after the operation. There were no significant differences in VAS pain scores between groups at 0, 12, 24 and 48 h after surgery ( P >0.05). Compared to Group S, the incidence of postoperative nausea, vomiting and lethargy was significantly lower in Group D ( P <0.05). Conclusion Dezocine increases the ratio of Th1/Th2 cytokines, relieves postoperative pain and causes fewer side effects in patients undergoing laparoscopic radical gastrectomy.

show abstract

Effects of dezocine and sufentanyl for postoperative analgesia on activity of NK, CD4+ and CD8+ cells in patients with breast cancer

Cited by 10 publications

References 26 publications

Dezocine inhibits cell proliferation, migration and invasion by targeting CRABP2 in ovarian cancer

Dezocine inhibits cell proliferation, migration and invasion by targeting CRABP2 in ovarian cancer

Dezocine inhibits cell proliferation, migration and invasion by targeting CRABP2 in ovarian cancer

Effect of Dezocine on the Ratio of Th1/Th2 Cytokines in Patients Receiving Postoperative Analgesia Following Laparoscopic Radical Gastrectomy: A Prospective Randomised Study

Contact Info

Product

Resources

About